Xencor to Present at the 2021 RBC Capital Markets Global Healthcare Virtual Conference
Get Alerts XNCR Hot Sheet
Join SI Premium – FREE
MONROVIA, Calif.--(BUSINESS WIRE)-- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a virtual fireside chat at the 2021 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 19, 2021 at 1:20 p.m. ET / 10:20 a.m. PT.
A live webcast will be available under "Events & Presentations" in the Investors section of the Company's website located at www.xencor.com. Following the webcast, a replay will be archived on the website for at least 30 days.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies and cytokines for the treatment of cancer and autoimmune diseases. Currently, 21 candidates engineered with Xencor's XmAb® technology are in clinical development internally and with partners. Xencor's XmAb antibody engineering technology enables small changes to the structure of proteins resulting in new mechanisms of therapeutic action. For more information, please visit www.xencor.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005938/en/
Charles Liles
[email protected]
Media Contact
Jason I. Spark
Canale Communications
619-849-6005
[email protected]
Source: Xencor, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Filing of Arkema’s 2023 Universal Registration Document
- LFTD Partners Inc. to Host Fourth Quarter and Full Year 2023 Earnings Conference Call on April 1, 2024
- Stillwater Critical Minerals Announces Private Placement with $2.1M Lead Order from Glencore
Create E-mail Alert Related Categories
Business Wire, Press ReleasesRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!